Top ▲
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 508 | 10q24.32 | CYP17A1 | cytochrome P450 family 17 subfamily A member 1 | |
| Mouse | - | 507 | 19 38.97 cM | Cyp17a1 | cytochrome P450, family 17, subfamily a, polypeptide 1 | |
| Rat | - | 507 | 1q54 | Cyp17a1 | cytochrome P450, family 17, subfamily a, polypeptide 1 | |
| Previous and Unofficial Names |
| Steroid 17-α-hydroxylase/17,20 lyase | cytochrome P450 17A1 | steroid 17-alpha hydroxylase | cytochrome P450, family 17, subfamily a, polypeptide 1 | cytochrome P450, family 17, subfamily A, polypeptide 1 | cytochrome P450 |
| Database Links |
|
| Alphafold | P05093 (Hs), P27786 (Mm), P11715 (Rn) |
| BRENDA | 1.14.14.19, 1.14.14.32 |
| ChEMBL Target | CHEMBL3522 (Hs), CHEMBL4430 (Rn) |
| DrugBank Target | P05093 (Hs) |
| Ensembl Gene | ENSG00000148795 (Hs), ENSMUSG00000003555 (Mm), ENSRNOG00000020035 (Rn) |
| Entrez Gene | 1586 (Hs), 13074 (Mm), 25146 (Rn) |
| Human Protein Atlas | ENSG00000148795 (Hs) |
| KEGG Enzyme | 1.14.14.19, 1.14.14.32 |
| KEGG Gene | hsa:1586 (Hs), mmu:13074 (Mm), rno:25146 (Rn) |
| OMIM | 609300 (Hs) |
| Orphanet | ORPHA120963 (Hs) |
| Pharos | P05093 (Hs) |
| SynPHARM |
78807 (in complex with abiraterone) 82517 (in complex with galeterone) |
| UniProtKB | P05093 (Hs), P27786 (Mm), P11715 (Rn) |
| Wikipedia | CYP17A1 (Hs) |
| Enzyme Reaction |
||||||||
|
||||||||
Download all structure-activity data for this target as a CSV file 
| Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immuno Process Associations | ||
|
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
1. Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW. (2003) Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol, 84 (5): 555-62. [PMID:12767280]
2. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman Jr D, Farquhar R, Guo Z, Qiu Y et al.. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem, 48 (8): 2972-84. [PMID:15828836]
3. Njar VC, Kato K, Nnane IP, Grigoryev DN, Long BJ, Brodie AM. (1998) Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J Med Chem, 41 (6): 902-12. [PMID:9526564]
4. Potter GA, Barrie SE, Jarman M, Rowlands MG. (1995) Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem, 38 (13): 2463-71. [PMID:7608911]
5. Wang A, Luo X, Meng X, Lu Z, Chen K, Yang Y. (2023) Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer. J Med Chem, 66 (14): 9972-9991. [PMID:37458396]
